XTLB

XTL Biopharmaceuticals Ltd. - ADR (XTLB) | Rumor.io

XTL Biopharmaceuticals

XTLB

Attention (50-day avg)0%

Attention rank (50-day avg)#4,883

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization5.5M

Earnings per share-0.36

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-7M

Social

What share of all stock conversation is about XTLB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% +0

Jul 1

XTL Biopharmaceuticals Ltd. completed the acquisition of Psyga Bio Ltd., gaining control of ~83.40% of Psyga Bio shares.
The acquisition marks a strategic expansion into psychedelic and functional mushroom-derived therapeutics, complementing the company's legacy autoimmune disease assets.
The company has $1.5 million on hand for trials, and the acquisition is seen as a potential catalyst for a significant price increase.

Generated by AI

Sentiment

Of the messages about XTLB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	86.96% +17.73
Bearish	—	—	—	13.04% -17.73

Bullish· Jul 1

XTLB is expected to make a significant move upwards following the completion of its acquisition, with some predicting it will fly past $4.00.
The company's low float and recent acquisition news make it a prime candidate for a double-digit stock, with some analysts expecting it to reach $5 or more.
XTLB's biotech status and the significant amount of money on hand for trials ($1.5 million) are expected to drive a strong market response, with some predicting an "Epic run" and a potential $JEM-type move.

Bearish· Apr 30

XTL Biopharmaceuticals Ltd. ($XTLB) is likely to open at a lower price tomorrow ($3.60).
The stock's price action is not fully trusted, despite its current strength.
Holding a long position in $XTLB is a high-risk strategy, potentially requiring a significant amount of capital ($25,000).

Generated by AI

Topics

Of the messages about XTLB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	0.86%
Analysts	—	—	—	0%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	98.24%
Technical Analysis	—	—	—	0.89%

Announcements· Apr 29

XTL Biopharmaceuticals ($XTLB) to acquire Psyga Bio in an all-share deal, granting Psyga shareholders 40% post-transaction ownership and up to 30% additional equity tied to milestones.
The acquisition will establish XTL as a leading psychedelic biotechnology platform with an advanced clinical pipeline, licensed GMP manufacturing, and proprietary psilocybin technologies.
The deal will add Psyga Bio's GMP facility and over 180 mushroom strains to XTL's portfolio, with 7 Phase 2a trials planned and a $1.5M private placement to fund the acquisition.

Technical Analysis· Apr 29

XTLB is showing a flag pattern, with a potential upside move if it clears the $4.10-$4.30 zone with strong volume.
The stock has been rejecting the $4.10 level of resistance, and needs to close above it for a potential bigger move to $4.5 or higher.
XTLB has a low float, making it a potentially volatile stock, and traders are watching for entry opportunities after market open if it maintains its current price movement.

Generated by AI

Community

Of the messages about XTLB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	1.37%
Newcomers	—	—	100%	98.63%

Regulars· Apr 29

$XTLB is a top watch after news of Trump's attempt to get psychedelics approved by the FDA.
XTL Biopharmaceuticals' acquisition of Psyga Bio is seen as a major development, establishing a leading psychedelic biotechnology platform.
$XTLB is on the uptrend, and needs to break resistance at 3.67 to continue its momentum.

Newcomers· Jul 1

Many newcomers are excited about the recent acquisition completion and the company's $1.5 million cash on hand for trials, which they believe will lead to a double-digit stock price.
Some users are holding onto the stock, expecting a nice move due to the acquisition news and the low float, and are hoping to see a run similar to other low float biotech stocks like $JEM.
Newcomers are anticipating a market response to the acquisition news, with some expecting a huge price increase, and others expecting a massive breakout, but all are excited about the stock's potential.

Generated by AI

News

XTL Biopharmaceuticals Regains Nasdaq Compliance and Enters One-Year Monitoring Period

Detailed price information for Xtl Biopharma ADR (XTLB-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Also Discussed

Investors talking about XTLB also mention

#	Name	Attention
1	EUDA Health Holdings LimitedEUDA	0%new
2	EpicQuest Education Group International LimitedEEIQ	0%0
3	Zhongchao Inc. Class A Ordinary SharesZCMD	0%new
4	Oxbridge Re Holdings LimitedOXBRW	0%0
5	Onfolio Holdings, Inc.ONFO	0%-0.05
6	BTCM - BIT Mining Limited	——
7	Fibrobiologics Inc.FBLG	0%0
8	Inno Holdings Inc.INHD	0%new
9	GlucoTrack Inc.GCTK	0%0
10	Pineapple Financial Inc.PAPL	0%+0

XTL Biopharmaceuticals Ltd. - ADR

Healthcare
Biotechnology

XTL Biopharmaceuticals Ltd. - ADR is the American Depositary Receipt for shares of XTL Biopharmaceuticals Ltd., an Israel-based biopharmaceutical company. The company focuses on the acquisition, development, and commercialization of pharmaceutical products targeting unmet medical needs, particularly in autoimmune diseases. Its lead candidate, hCDR1, is a Phase II-ready therapeutic designed to treat systemic lupus erythematosus and Sjogren’s syndrome through a proprietary mechanism of action. Additional assets in its pipeline include recombinant human erythropoietin (rHuEPO). XTL Biopharmaceuticals Ltd. maintains a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 across various indications. Headquartered in Ramat Gan, Israel, and founded in 1993, the company operates within the biopharmaceutical sector, advancing innovative solutions to improve patient outcomes in challenging therapeutic areas.

Website

Location

85 Medinat Hayehudim St.

Herzliya, 4676670

Israel

Social

What share of all stock conversation is about XTLB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% +0

Jul 1

XTL Biopharmaceuticals Ltd. completed the acquisition of Psyga Bio Ltd., gaining control of ~83.40% of Psyga Bio shares.
The acquisition marks a strategic expansion into psychedelic and functional mushroom-derived therapeutics, complementing the company's legacy autoimmune disease assets.
The company has $1.5 million on hand for trials, and the acquisition is seen as a potential catalyst for a significant price increase.

Generated by AI

Sentiment

Of the messages about XTLB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	86.96% +17.73
Bearish	—	—	—	13.04% -17.73

Bullish· Jul 1

XTLB is expected to make a significant move upwards following the completion of its acquisition, with some predicting it will fly past $4.00.
The company's low float and recent acquisition news make it a prime candidate for a double-digit stock, with some analysts expecting it to reach $5 or more.
XTLB's biotech status and the significant amount of money on hand for trials ($1.5 million) are expected to drive a strong market response, with some predicting an "Epic run" and a potential $JEM-type move.

Bearish· Apr 30

XTL Biopharmaceuticals Ltd. ($XTLB) is likely to open at a lower price tomorrow ($3.60).
The stock's price action is not fully trusted, despite its current strength.
Holding a long position in $XTLB is a high-risk strategy, potentially requiring a significant amount of capital ($25,000).

Generated by AI

Topics

Of the messages about XTLB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	0.86%
Analysts	—	—	—	0%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	98.24%
Technical Analysis	—	—	—	0.89%

Announcements· Apr 29

XTL Biopharmaceuticals ($XTLB) to acquire Psyga Bio in an all-share deal, granting Psyga shareholders 40% post-transaction ownership and up to 30% additional equity tied to milestones.
The acquisition will establish XTL as a leading psychedelic biotechnology platform with an advanced clinical pipeline, licensed GMP manufacturing, and proprietary psilocybin technologies.
The deal will add Psyga Bio's GMP facility and over 180 mushroom strains to XTL's portfolio, with 7 Phase 2a trials planned and a $1.5M private placement to fund the acquisition.

Technical Analysis· Apr 29

XTLB is showing a flag pattern, with a potential upside move if it clears the $4.10-$4.30 zone with strong volume.
The stock has been rejecting the $4.10 level of resistance, and needs to close above it for a potential bigger move to $4.5 or higher.
XTLB has a low float, making it a potentially volatile stock, and traders are watching for entry opportunities after market open if it maintains its current price movement.

Generated by AI

Community

Of the messages about XTLB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	1.37%
Newcomers	—	—	100%	98.63%

Regulars· Apr 29

$XTLB is a top watch after news of Trump's attempt to get psychedelics approved by the FDA.
XTL Biopharmaceuticals' acquisition of Psyga Bio is seen as a major development, establishing a leading psychedelic biotechnology platform.
$XTLB is on the uptrend, and needs to break resistance at 3.67 to continue its momentum.

Newcomers· Jul 1

Many newcomers are excited about the recent acquisition completion and the company's $1.5 million cash on hand for trials, which they believe will lead to a double-digit stock price.
Some users are holding onto the stock, expecting a nice move due to the acquisition news and the low float, and are hoping to see a run similar to other low float biotech stocks like $JEM.
Newcomers are anticipating a market response to the acquisition news, with some expecting a huge price increase, and others expecting a massive breakout, but all are excited about the stock's potential.

Generated by AI

XTL Biopharmaceuticals

Social

Jul 1

Bullish· Jul 1

Bearish· Apr 30

Announcements· Apr 29

Technical Analysis· Apr 29

Regulars· Apr 29

Newcomers· Jul 1

XTL Biopharmaceuticals Regains Nasdaq Compliance and Enters One-Year Monitoring Period

Also Discussed

XTL Biopharmaceuticals Ltd. - ADR

Company Information

Location

XTL Biopharmaceuticals Regains Nasdaq Compliance and Enters One-Year Monitoring Period

Also Discussed

Social

Jul 1

Bullish· Jul 1

Bearish· Apr 30

Announcements· Apr 29

Technical Analysis· Apr 29

Regulars· Apr 29

Newcomers· Jul 1